Research Library

In a country steeped in political corruption, the Sept. 3 resignation of Guatemala's President Otto Pérez Molina is the first step toward the country's redemption, writes Latin America Initiative program director Erika de la Garza.

A new White House initiative to address rising U.S. heroin use will increase funds to pinpoint the sources of heroin as well as hot spots for drug overdoses. Baker Institute Blog: http://bit.ly/1h0W7r2

Iran — as it has since the Islamic Revolution of 1979 — represents a challenge to U.S. foreign policy. But it is one best addressed through a combination of firm action where necessary and flexible diplomacy where possible.

Part 2 of a two-part blog on China’s economy. Part 1 can be found here.

At this point, projections indicate that a…

In a two-part blog, Russell Green, Will Clayton Fellow in International Economics, examines whether a slowdown of China's powerhouse economy will impact the country's global agenda.

This week, negotiators announced the framework of a nuclear agreement — ultimately, a Joint Comprehensive Plan of Action (JCPOA) — with Iran. If a final deal can be struck and if the agreement holds, this deal will mark a historic foreign policy achievement, writes Joe Barnes.

The deepening civil war in Yemen poses more challenges than solutions for Saudi Arabia, writes Middle East scholar Andrew Bowen.

Drug policy has experienced an interesting shift recently. Along with legalization of medical and recreational marijuana, many states are also reducing penalties for nonviolent drug offenses and placing greater focus on treatment for drug users. The emphasis on treatment and rehabilitation for drug users is the result of many factors, including recognition that the drug war has not reduced drug use, a desire to reduce the prison population and save money, and a surge in the rate of overdoses from opioid and heroin use. What remains to be seen is whether the current popularity of drug treatment will become a more permanent feature of drug policy. In this Baker Institute Viewpoints series, five experts on drug policy examine the question, “Is the current emphasis on treatment in drug policy a short-term trend or is it here to stay?”